Lupin Vilfuro 100 Capsule contains a combination of Fluticasone Furoate (100 mcg) and Vilanterol (25 mcg), indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients requiring both a corticosteroid and a long-acting beta2-adrenergic agonist (LABA). Fluticasone Furoate is a potent inhaled corticosteroid that exerts anti-inflammatory effects by inhibiting multiple cell types and mediators involved in airway inflammation, thereby reducing airway hyperresponsiveness and improving lung function. Vilanterol is a selective, long-acting beta2-adrenergic receptor agonist that induces bronchodilation by relaxing airway smooth muscle, leading to sustained improvement in airflow. The fixed-dose combination in Lupin Vilfuro 100 Capsule provides synergistic benefits, enhancing symptom control, reducing exacerbations, and improving quality of life in patients with obstructive airway diseases. It is administered once daily, facilitating adherence to therapy. The medication should be used under medical supervision, with caution in patients with cardiovascular disorders, hypersensitivity to components, or those at risk of systemic corticosteroid effects. Regular monitoring of lung function and symptom control is recommended to optimize treatment outcomes. Lupin Vilfuro 100 Capsule is not intended for relief of acute bronchospasm.